[Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children]

Hui Jiang1, Jing-yan Tang, Na Zhang

  • 1Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200040, China.

Insights

This study evaluated the ALL-2005 protocol for older children with acute lymphoblastic leukemia (ALL). The ALL-2005 regimen showed promising outcomes, but BCR-ABL translocation indicates a poorer prognosis in these patients.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Trial Analysis

Context:

  • Acute lymphoblastic leukemia (ALL) in older children (10-18 years) presents unique challenges.
  • Evaluating multicenter cooperation regimens is crucial for optimizing treatment strategies.
  • The ALL-2005 protocol was implemented across five centers for newly diagnosed ALL patients.

Purpose:

  • To retrospectively analyze clinical characteristics of older children diagnosed with ALL.
  • To evaluate treatment outcomes, including event-free survival (EFS) and overall survival (OS), using the ALL-2005 protocol.
  • To identify prognostic factors influencing survival in this patient cohort.

Summary:

  • The study included 103 newly diagnosed ALL patients (aged 10-18 years) treated with the ALL-2005 protocol.
  • Achieved a 94.2% complete remission rate; however, 36.9% of patients died during treatment.
  • The 5-year EFS and OS were 60.2% and 64.1%, respectively. Age (14-18 years) and BCR-ABL translocation were identified as independent risk factors for poorer EFS.

Impact:

  • The ALL-2005 protocol demonstrates feasibility and provides valuable survival data for older childhood ALL.
  • Identifies specific risk factors (age, BCR-ABL translocation) crucial for risk stratification and personalized treatment.
  • Recommends the ALL-2005 protocol for older childhood ALL, emphasizing the need for intensified therapy in high-risk cases.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...